Endoplasmic Reticulum Stress in Systemic Lupus Erythematosus and Lupus Nephritis: Potential Therapeutic Target

被引:4
|
作者
Li, Hui-Yuan [1 ]
Huang, Li-Feng [1 ]
Huang, Xiao-Rong [1 ]
Wu, Dan [1 ]
Chen, Xiao-Cui [1 ]
Tang, Ji-Xin [1 ]
An, Ning [1 ]
Liu, Hua-Feng [1 ]
Yang, Chen [1 ]
机构
[1] Guangdong Med Univ, Guangdong Prov Key Lab Autophagy & Major Chron Non, Key Lab Prevent & Management Chron Kidney Dis Zhan, Inst Nephrol,Affiliated Hosp, Zhanjiang 524001, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
UNFOLDED PROTEIN RESPONSE; TUBULAR EPITHELIAL-CELLS; PLASMACYTOID DENDRITIC CELLS; INDUCED PODOCYTE APOPTOSIS; ER STRESS; URSODEOXYCHOLIC ACID; TRANSCRIPTION FACTOR; MESANGIAL CELLS; QUALITY-CONTROL; TLR ACTIVATION;
D O I
10.1155/2023/7625817
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) is a complex autoimmune disease. Approximately one-third to two-thirds of the patients with SLE progress to lupus nephritis (LN). The pathogenesis of SLE and LN has not yet been fully elucidated, and effective treatment for both conditions is lacking. The endoplasmic reticulum (ER) is the largest intracellular organelle and is a site of protein synthesis, lipid metabolism, and calcium storage. Under stress, the function of ER is disrupted, and the accumulation of unfolded or misfolded proteins occurs in ER, resulting in an ER stress (ERS) response. ERS is involved in the dysfunction of B cells, macrophages, T cells, dendritic cells, neutrophils, and other immune cells, causing immune system disorders, such as SLE. In addition, ERS is also involved in renal resident cell injury and contributes to the progression of LN. The molecular chaperones, autophagy, and proteasome degradation pathways inhibit ERS and restore ER homeostasis to improve the dysfunction of immune cells and renal resident cell injury. This may be a therapeutic strategy for SLE and LN. In this review, we summarize advances in this field.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Systemic lupus erythematosus and lupus nephritis
    Koutsokeras, Toli
    Healy, Tina
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (03) : 1 - 2
  • [2] Systemic lupus erythematosus and lupus nephritis
    Toli Koutsokeras
    Tina Healy
    [J]. Nature Reviews Drug Discovery, 2014, 13 : 173 - 174
  • [3] Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis
    Marks, Stephen D.
    Tullus, Kjell
    [J]. ACTA PAEDIATRICA, 2010, 99 (07) : 967 - 974
  • [4] Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis
    Beckwith, Hannah
    Lightstone, Liz
    [J]. NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 250 - 254
  • [5] Bullous Systemic Lupus Erythematosus With Lupus Nephritis
    Musicante, Meryl
    Shroyer, Whitney
    Tirado, Mariantonieta
    [J]. MAYO CLINIC PROCEEDINGS, 2023, 98 (07) : 1096 - 1097
  • [6] Endoplasmic Reticulum Stress Promotes the Development and Progression of Lupus Nephritis
    Boesen, Erika I.
    Bonnemaison, Mathilde L.
    [J]. FASEB JOURNAL, 2018, 32 (01):
  • [7] Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus
    Jing Li
    Hai-Feng Pan
    Han Cen
    Jing Tian
    Yan Ma
    Jin-Hui Tao
    Dong-Qing Ye
    [J]. Molecular Biology Reports, 2011, 38 : 4077 - 4081
  • [8] Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus
    Li, Jing
    Pan, Hai-Feng
    Cen, Han
    Tian, Jing
    Ma, Yan
    Tao, Jin-Hui
    Ye, Dong-Qing
    [J]. MOLECULAR BIOLOGY REPORTS, 2011, 38 (06) : 4077 - 4081
  • [9] Potential therapeutic target genes for systemic lupus erythematosus: a bioinformatics analysis
    Yu, Yun
    Liu, Liang
    Hu, Long-Long
    Yu, Ling-Ling
    Li, Jun-Pei
    Rao, Jing-an
    Zhu, Ling-Juan
    Liang, Qian
    Zhang, Rong-Wei
    Bao, Hui-Hui
    Cheng, Xiao-Shu
    [J]. BIOENGINEERED, 2021, 12 (01) : 2810 - 2819
  • [10] FAR in systemic lupus erythematosus: a potential biomarker of disease activity and lupus nephritis
    Xu, Jili
    Zhang, Hongmei
    Che, Nan
    Wang, Hengjin
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 4779 - 4785